Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14)

📊 Statistics

Analyst 1 Year Price Target: -
Upside/Downside from Analyst Target: -
Broker Call: 1
Dividend Minimum 3 Year Yield: 6.44%
EPS Growth Range (1Y): 100-200%
Net Income Growth Range (1Y): 100-200%
Revenue Growth Range (1Y): <0%

💰 Dividend History

Year	Annual Yield (%)	Total Amount	Current Yield (%)	Ex Date	Pay Date	Particulars
2025	-	$1.280000	6.92%	2025-06-25	2025-07-04	Rate: CNY 1.28 Per Security
2025	-	Total Amount for 2025: $1.280000
2024	7.29%	$1.280000	7.29%	2024-07-02	2024-07-12	Rate: CNY 1.28 Per Security
2024	7.29%	Total Amount for 2024: $1.280000
2023	6.90%	$1.120000	6.90%	2023-05-26	2023-06-06	Rate: CNY 1.12 Per Security
2023	6.90%	Total Amount for 2023: $1.120000
2022	6.44%	$0.500000	6.44%	2022-05-24	2022-06-02	Rate: CNY 0.5 Per Security
2022	6.44%	Total Amount for 2022: $0.500000

📅 SGX Earnings Announcements for T14

Date of Broadcast	Title	Financial Year Ended
2025-04-29 17:17	First Quarter Results	2025/03/31
2025-03-28 20:47	Full Yearly Results	2024/12/31
2024-10-30 17:21	Third Quarter Results	2024/09/30
2024-08-14 17:56	Second Quarter and/ or Half Yearly Results	2024/06/30
2024-04-29 17:25	First Quarter Results	2024/03/31
2024-03-29 19:56	Full Yearly Results	2023/12/31
2023-10-30 18:28	Third Quarter Results	2023/09/30
2023-08-14 17:31	Second Quarter and/ or Half Yearly Results	2023/06/30
2023-04-28 17:21	First Quarter Results	2023/03/31
2023-04-04 17:34	Full Yearly Results	2022/12/31
2023-03-31 19:30	Full Yearly Results	2022/12/31
2022-10-28 18:50	Third Quarter Results	2022/09/30
2022-08-12 18:36	Second Quarter and/ or Half Yearly Results	2022/06/30
2022-04-29 17:22	First Quarter Results	2022/03/31
2022-03-30 21:26	Full Yearly Results	2021/12/31

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14)

Market: SGX | Currency: USD

Address: No. 17 Baidi Road

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao Jiuxin pills, Qingyan drop pills, Jingwanhong ointment, Angong Niuhuang pills, Qingfei pills, anti-inflammatory pills, Qinggong Shoutao pills, Biqi capsules, Niuhuang Qingxin pills, Tongmai Yangxin pills, and Show more

📈 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Historical Chart

📰 Related News & Research

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Full Year Financial Statement and Dividend Announcement
March 30, 2025

Financial Analysis Report for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Business Description: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is a joint…
Tianjin Pharmaceutical Da Ren Tang Q3 2024 Financial Analysis: 6% Net Profit Decline Amid TCM-Focused Growth Strategy
October 30, 2024

Financial Analysis Report: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited – Q3 2024 Business Overview Core Operations and Segments: Tianjin Pharmaceutical Da Ren Tang…

🔍 View more Reports